Table 3.
Folic-acid conjugated NPs
| NP type | NP size (nm) | Tumor nature | In vitro model | In vivo model | Administration routes | References |
|---|---|---|---|---|---|---|
| Lipid-polymer hybrid NP | 102.4±4 | Breast cancer | MCF-7 cells | Nude mice | Tail vein injection | (63) |
| Lipid-polymer hybrid NP | 92.8±2.1 | Brain cancer | U87 cells | BALB/c nude mice | Intravenous injection | (64) |
| Lipid-polymer hybrid NP | 102.4±4 | Breast cancer | MCF-7 cells | BALB/c nude mice | Tail vein injection | (65) |
| Phospholipid-polyethylene glycol | 17.6 | Brain and breast cancer | U87 and MCF-7 cells | – | – | (66) |
| ICG-FA-PPD | 20.2 | Brain cancer | U87 cells | BALB/c nude mice | Intravenous injection | (67) |
| Micelle | 43.8 or 28.2 | – | KB cells | Female nude mice | Tail vein injection | (68) |
Abbreviations: ICG: indocyanine green; FA: folic acid; PPD: PEI(polyethylenimine)-PEG(polyethylene glycol)-gadoteric acid (Gd- DOTA).